Sydbank analyst: GSK news could help Bavarian Nordic in partner hunt

GSK has released positive data for its RSV vaccine, and according to Søren Løntoft Hansen, senior analyst at Sydbank, this could rub off positively on Bavarian’s partner search.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Bavarian Nordic is on the hunt for a partner to collaborate with on its RSV vaccine, and according to senior analyst at Sydbank Søren Løntoft Hansen, that hunt may just have got easier.

Competitor GSK has just released positive news about the phase III study of its own RSV vaccine, and this could inspire potential partners to come forward to support Bavarian, he says.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs